Investing.com - Haleon shares fell after the consumer health group reported weaker-than-expected organic sales growth in Q4 and issued a cautious near-term outlook.
As of 08:12 GMT, the stock declined over 4% in London morning trading.
Get sharper corporate earnings insights with InvestingPro
Organic sales growth in Q4 was 2.1%, below the 3.5% consensus expected by Jefferies. Volume declined by 0.3%, while price increases were about 2.4%, roughly in line with expectations.
The company noted that the cold and flu season caused a 1.5 percentage point drag, mainly due to weakness in Central Europe, which is expected to continue into Q1.
North American sales declined 1.0% year-over-year, roughly in line with forecasts, but volume was disappointing at -3.7%, a key metric since the company previously guided about -1% for the region. Emerging markets growth slowed to approximately 5.7%, down from 7.1% in Q3, with Brazil marked as a weak spot.
Haleon’s full-year profit margin was 22.9%, above the 22.6% consensus estimate.
Looking ahead, the company guided for 3-5% organic sales growth in 2026, below the approximately 4.6% consensus expected by Visible Alpha. Management cited the weak cold and flu season and challenging consumer environment as reasons for a more cautious near-term outlook, while reaffirming a mid-term growth target of 4-6% after this year.
Jefferies analyst David Hayes said in a post-earnings report: “We are concerned this is not good enough.” “The guidance was downgraded to 3-5% (from 4-6% mid-term guidance). We expect HLN to perform significantly poorly this morning.”
“He added that the 1.5 percentage point drag was mainly due to Europe, caused by a weak cold and flu season. However, he believes this dynamic was not fully priced in before the Q4 close.”
Haleon expects operating profit margins to grow at a high single-digit organic rate, approaching 24%, above the nearly 23.2% consensus. The company also noted that if current exchange rates persist, currency effects will reduce sales and operating profit by about 1 percentage point, and guided for a tax rate of 24.5%.
This article was translated with the assistance of artificial intelligence. For more information, see our Terms of Use.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Haleon stock price plummeted due to weak Q4 sales and cautious guidance for 2026
Investing.com - Haleon shares fell after the consumer health group reported weaker-than-expected organic sales growth in Q4 and issued a cautious near-term outlook.
As of 08:12 GMT, the stock declined over 4% in London morning trading.
Get sharper corporate earnings insights with InvestingPro
Organic sales growth in Q4 was 2.1%, below the 3.5% consensus expected by Jefferies. Volume declined by 0.3%, while price increases were about 2.4%, roughly in line with expectations.
The company noted that the cold and flu season caused a 1.5 percentage point drag, mainly due to weakness in Central Europe, which is expected to continue into Q1.
North American sales declined 1.0% year-over-year, roughly in line with forecasts, but volume was disappointing at -3.7%, a key metric since the company previously guided about -1% for the region. Emerging markets growth slowed to approximately 5.7%, down from 7.1% in Q3, with Brazil marked as a weak spot.
Haleon’s full-year profit margin was 22.9%, above the 22.6% consensus estimate.
Looking ahead, the company guided for 3-5% organic sales growth in 2026, below the approximately 4.6% consensus expected by Visible Alpha. Management cited the weak cold and flu season and challenging consumer environment as reasons for a more cautious near-term outlook, while reaffirming a mid-term growth target of 4-6% after this year.
Jefferies analyst David Hayes said in a post-earnings report: “We are concerned this is not good enough.” “The guidance was downgraded to 3-5% (from 4-6% mid-term guidance). We expect HLN to perform significantly poorly this morning.”
“He added that the 1.5 percentage point drag was mainly due to Europe, caused by a weak cold and flu season. However, he believes this dynamic was not fully priced in before the Q4 close.”
Haleon expects operating profit margins to grow at a high single-digit organic rate, approaching 24%, above the nearly 23.2% consensus. The company also noted that if current exchange rates persist, currency effects will reduce sales and operating profit by about 1 percentage point, and guided for a tax rate of 24.5%.
This article was translated with the assistance of artificial intelligence. For more information, see our Terms of Use.